Medication adherence in patients with Parkinson's disease

CNS Drugs

Volumn 29, Issue 1, 2014, Pages 47-53

  Malek, Naveed ^a   Grosset, Donald G ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; RASAGILINE; ROTIGOTINE;

AGE; ARTICLE; ATTITUDE TO ILLNESS; COGNITION; COMORBIDITY; COMPREHENSION; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; DRUG HALF LIFE; DYSKINESIA; EMPLOYMENT; FAMILY ATTITUDE; FAMILY THERAPY; HALLUCINATION; HUMAN; HYPERPYREXIA; KNOWLEDGE; LOWEST INCOME GROUP; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; PARKINSON DISEASE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; REINFORCEMENT; REMINDER SYSTEM; SELF MONITORING; SPOUSE; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); WELLBEING; PSYCHOLOGY;

ANTIPARKINSON AGENTS; HUMANS; MEDICATION ADHERENCE; PARKINSON DISEASE;

EID: 84925463304     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0220-0     Document Type: Article

References (45)

1. Hughes DA, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics. 2001;19(12):1185-97.
2. Cramer JA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7.
3. Salzman C. Medication compliance in the elderly. J Clin Psychiatry. 1995;56(Suppl 1):18-22 discussion 23.
4. Grosset KA, et al. Measuring therapy adherence in Parkinson's disease: a comparison of methods. J Neurol Neurosurg Psychiatry. 2006;77(2):249-51.
5. Andrade SE, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-74 discussion 575-7.
6. Offord S, et al. Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with medicare coverage. Community Ment Health J. 2013;49(6):625-9.
7. Daley DJ, et al. Systematic review on factors associated with medication non-adherence in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(10):1053-61.
8. Valldeoriola F, et al. Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study. Eur J Neurol. 2011;18(7):980-7.
9. Kulkarni AS, et al. Medication adherence and associated outcomes in Medicare health maintenance organization-enrolled older adults with Parkinson's disease. Mov Disord. 2008;23(3):359-65.
10. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord. 2004;19(5):513-7.
11. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005;20(11):1502-7.
12. Grosset D, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009;24(6):826-32.
13. Wei YJ, et al. Antiparkinson drug use and adherence in Medicare Part D beneficiaries with Parkinson's disease. Clin Ther. 2013;35(10):1513-25 e1.
14. Sesar A, Arbelo JM, del Val JL. Treatment of Parkinson disease, time and dosage: "does simple dosage facilitate compliance and therapeutic goals?". Neurologist. 2011;17(6 Suppl 1):S43-6.
15. Leoni O, et al. Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf. 2002;11(2):149-57.
16. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord. 2005;20(11):1397-404.
17. Saini SD, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22-33.
18. Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010;257(Suppl 2):S253-61.
19. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 1994;17(Suppl 2):S32-44.
20. Stocchi F, et al. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24(10):2883-95.
21. Hametner EM, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clin Interv Aging. 2012;7:83-8.
22. Tarrants ML, et al. Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother. 2010;8(4):374-83.
23. Schnitzler A, Leffers KW, Hack HJ. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2010;16(8):513-6.
24. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677-87.
25. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs. 1998;55(Suppl 1):1-9.
26. Grosset D. Therapy adherence issues in Parkinson's disease. J Neurol Sci. 2010;289(1-2):115-8.
27. Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136-40.
28. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs. 2009;23(2):157-70.
29. Richy FF, et al. Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis. Appl Health Econ Health Policy. 2013;11(4):395-406.
30. Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010;25(4):474-80.
31. Wei YJ, et al. Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population. Value Health. 2014;17(2):196-204.
32. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm. 1991;48(9):1978-88.
33. Galloway R, McGuire J. Determinants of compliance with iron supplementation: supplies, side effects, or psychology? Soc Sci Med. 1994;39(3):381-90.
34. Berger BA. Assessing and interviewing patients for meaningful behavioral change: part 1. Case Manager. 2004;15(5):46-50 quiz 51.
35. Llorca PM. Discussion of prevalence and management of discomfort when swallowing pills: orodispersible tablets expand treatment options in patients with depression. Ther Deliv. 2011;2(5):611-22.
36. Korczyn AD, et al. Rotigotine transdermal system for perioperative administration. J Neural Transm. 2007;114(2):219-21.
37. Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial. BMC Neurol. 2007;7:20.
38. Daley DJ, et al. Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: a randomised controlled trial. Int J Clin Pract. 2014;68(8):963-71.
39. Rojo A, et al. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord. 2003;10(1):23-8.
40. Riedel O, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease: results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol. 2008;255(2):255-64.
41. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101-7.
42. Qureshi SU, et al. Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression. J Geriatr Psychiatry Neurol. 2012;25(4):233-9.
43. Campbell NL, et al. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother. 2012;10(3):165-77.
44. Haynes RB, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.
45. Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S; NINDS NET-PD Investigators and Coordinators. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord. 2007;22(6):822-7.